December 5^th at 12:00
Onsite event
in Presidentti auditorium, BioCity

Prof. Bernhard Küster, Technical University of Munich, Germany
Cancer patient and drug proteome profiling enhance treatment recommendations in molecular tumor boards
Host: Jukka Westermarck (jukka.westermarck@utu.fi)

Coffee and sandwich at 11:45, first come first served!

Six PhD researchers and early-career postdocs are welcome to have a lunch and discuss with Prof. Küster after the seminar. This is a great possibility to learn hosting skills in a friendly environment and create connections for future. Everyone is welcome to join, BioCity Turku will offer the lunch.

If you got interested, please send an email to biocityturku@bioscience.fi

Prof. Küster leads Proteomics and Bioanalytics group at the Technical University of Munich, which comprises an international research team with a focus on proteomics and chemical biology. Most of their research builds on the powerful combination of cell biology, chemistry, biochemistry, mass spectrometry and bioinformatics. The group develops novel analytical methods for quantitative proteome research notably for high throughput applications and the analysis of post translational protein modifications (PTMs). In their chemical biology efforts, they elucidate the selectivity of drug-target interactions on a proteome-wide scale, investigate the cellular mechanisms by which drugs exert their function and identify mechanisms of cancer therapy resistance. In addition, the group investigates phosphoproteomic signaling events as biomarkers for patient stratification, as well as indicators of drug effectiveness and treatment response.

Selected publications

Chang YC, Gnann C, Steimbach RR, Bayer FP, Lechner S, Sakhteman A, Abele M, Zecha J, Trendel J, The M, Lundberg E, Miller AK, Kuster B. 2024. Decrypting lysine deacetylase inhibitor action and protein modifications by dose-resolved proteomics. Cell Rep. 43(6):114272. doi: 10.1016/j.celrep.2024.114272

Eckert S, Berner N, Kramer K, Schneider A, Müller J, Lechner S, Brajkovic S, Sakhteman A, Graetz C, Fackler J, Dudek M, Pfaffl MW, Knolle P, Wilhelm S, Kuster B. 2024. Decrypting the molecular basis of cellular drug phenotypes by dose-resolved expression proteomics. Nat Biotechnol. doi: 10.1038/s41587-024-02218-y

Reinecke M, Brear P, Vornholz L, Berger BT, Seefried F, Wilhelm S, Samaras P, Gyenis L, Litchfield DW, Médard G, Müller S, Ruland J, Hyvönen M, Wilhelm M, Kuster B. 2024. Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors. Nat Chem Biol. 20(5):577-585. doi: 10.1038/s41589-023-01459-3.

Lechner S, Steimbach RR, Wang L, Deline ML, Chang YC, Fromme T, Klingenspor M, Matthias P, Miller AK, Médard G, Kuster B. 2026. Chemoproteomic target deconvolution reveals Histone Deacetylases as targets of (R)-lipoic acid. Nat Commun. 14(1):3548. doi: 10.1038/s41467-023-39151-8.

General information

• You can download and save all the autumn 2024 FoS-seminars to your calendar from here: https://seafile.utu.fi/d/44a70f80ac1e46a9ad0a/
• Registration is not needed, participation list is circulated in the audience
• If you are a student and later wish to get a certificate of attendance from the Frontier of Science seminars, print out the seminar diary and after the seminar ask the BioCity coordinator to sign it https://seafile.utu.fi/d/44a70f80ac1e46a9ad0a/
• Please note that any audio or video recording of the seminars is strictly forbidden.
• Autumn 2024 image credits to Mia Åstrand: Details of the Bacteroides fragilis VgrG protein (PDB ID: 8GRA). Image created in the PyMOL Molecular Graphics System, Version 2.5 Schrödinger, LLC.